These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 23651945)

  • 21. Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic--comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia Study.
    Pusswald G; Moser D; Gleiss A; Janzek-Hawlat S; Auff E; Dal-Bianco P; Lehrner J
    Alzheimers Dement; 2013 Jul; 9(4):366-76. PubMed ID: 23164551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
    Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
    Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease.
    Hall A; Muñoz-Ruiz M; Mattila J; Koikkalainen J; Tsolaki M; Mecocci P; Kloszewska I; Vellas B; Lovestone S; Visser PJ; Lötjonen J; Soininen H; ; ;
    J Alzheimers Dis; 2015; 44(1):79-92. PubMed ID: 25201784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T; Hänninen T; Tunnard C; Hallikainen M; Mecocci P; Sobow T; Tsolaki M; Vellas B; Lovestone S; Soininen H
    J Alzheimers Dis; 2014; 39(3):679-90. PubMed ID: 24246420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia.
    Viticchi G; Falsetti L; Buratti L; Sajeva G; Luzzi S; Bartolini M; Provinciali L; Silvestrini M
    J Alzheimers Dis; 2017; 59(1):67-75. PubMed ID: 28582863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mild cognitive impairment: clinical and imaging profile in a memory clinic setting in India.
    Alladi S; Shailaja M; Mridula KR; Haritha CA; Kavitha N; Khan SA; Divyaraj G; Kaul S
    Dement Geriatr Cogn Disord; 2014; 37(1-2):113-24. PubMed ID: 24135787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Searching for Primary Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Multivariate Follow-Up Study.
    López ME; Turrero A; Cuesta P; López-Sanz D; Bruña R; Marcos A; Gil P; Yus M; Barabash A; Cabranes JA; Maestú F; Fernández A
    J Alzheimers Dis; 2016 Mar; 52(1):133-43. PubMed ID: 27060953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression.
    Furney SJ; Kronenberg D; Simmons A; Güntert A; Dobson RJ; Proitsi P; Wahlund LO; Kloszewska I; Mecocci P; Soininen H; Tsolaki M; Vellas B; Spenger C; Lovestone S
    J Alzheimers Dis; 2011; 26 Suppl 3():395-405. PubMed ID: 21971479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between executive dysfunction and hippocampal volume in Alzheimer's disease.
    Nagata T; Shinagawa S; Ochiai Y; Aoki R; Kasahara H; Nukariya K; Nakayama K
    Int Psychogeriatr; 2011 Jun; 23(5):764-71. PubMed ID: 21106135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.
    Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M
    Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting progression from cognitive impairment to Alzheimer's disease with the Disease State Index.
    Hall A; Mattila J; Koikkalainen J; Lötjonen J; Wolz R; Scheltens P; Frisoni G; Tsolaki M; Nobili F; Freund-Levi Y; Minthon L; Frölich L; Hampel H; Visser PJ; Soininen H
    Curr Alzheimer Res; 2015; 12(1):69-79. PubMed ID: 25523428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.
    Kida J; Nemoto K; Ikejima C; Bun S; Kakuma T; Mizukami K; Asada T
    J Alzheimers Dis; 2016; 51(2):405-15. PubMed ID: 26890740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Tan YJ; Ng ASL; Vipin A; Lim JKW; Chander RJ; Ji F; Qiu Y; Ting SKS; Hameed S; Lee TS; Zeng L; Kandiah N; Zhou J
    J Alzheimers Dis; 2017; 58(2):413-423. PubMed ID: 28453482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.
    Wagner M; Wolf S; Reischies FM; Daerr M; Wolfsgruber S; Jessen F; Popp J; Maier W; Hüll M; Frölich L; Hampel H; Perneczky R; Peters O; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Lewczuk P; Kornhuber J; Wiltfang J
    Neurology; 2012 Feb; 78(6):379-86. PubMed ID: 22238414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.